Efficacy and safety of bi-weekly pegfilgrastim for dose-dense chemotherapy-induced neutropenia in breast cancer patients

Hitomi Mori, Makoto Kubo, Masaya Kai, Kanako Kurata, Mai Yamada, Masafumi Nakamura

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Aim: The dose-dense doxorubicin and cyclophosphamide (ddAC) for patients with HER-2negative breast cancer is recommended by the National Comprehensive Cancer Network guideline in US. However, there are little data on serum G-CSF concentrations in patients undergoing bi-weekly dose-dense therapy with pegfilgrastim. The objective of this study was to compare the serum G-CSF concentrations in patients receiving pegfilgrastim in bi- or tri-weekly regimens. Patients and Methods: This study included 26 patients who received ddAC or docetaxel and cyclophosphamide (TC) for primary breast cancer. Serum G-CSF concentrations were measured by ELISA. Results: Serum G-CSF concentrations peaked in the second week of ddAC cases and in the ninth week of TC cases. Neutrophils gradually increased until the sixth week in ddAC cases, while they were slightly decreased during the first three weeks in TC cases. Treatments were completed without febrile neutropenia or treatment delays. Conclusion: Primary prophylactic pegfilgrastim administrations increased serum G-CSF concentrations, helping to maintain the absolute neutrophil counts that are required to undergo chemotherapy. The treatment of ddAC with 3.6 mg pegfilgrastim is completely safe for female Japanese patients.

Original languageEnglish
Pages (from-to)4381-4386
Number of pages6
JournalAnticancer research
Volume38
Issue number7
DOIs
Publication statusPublished - Jul 2018
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy and safety of bi-weekly pegfilgrastim for dose-dense chemotherapy-induced neutropenia in breast cancer patients'. Together they form a unique fingerprint.

Cite this